Figure 3. Evaluation of 68Ga-HZ20 in the rhACE2
intratumoral model based on A549 cells. (A) PET imaging at 60 min after68Ga-HZ20 injection following intratumoral injection
of different doses of rhACE2. The white box with a dashed line indicates
the tumor and the injection site of rhACE2 (K, B stands for kidney and
bladder). (B) Comparison of SUVmax in the tumors in Figure 3A and Figure
S6. (C) The ratio of tumor to muscle SUVmax at different time points
following 68Ga-HZ20 injection. (D) Ex vivo PET
imaging of tumor tissue treated with different doses of rhACE2. (E)
Comparison of % ID/g in tumor tissue treated with different doses of
rhACE2. (F) Correlation analysis between SUVmax and rhACE2 doses at 30
min after injection. (G) Western blot of rhACE2 at the injection site.